Nanopharm, an Aptar Pharma company and provider of contract research and development services for orally inhaled and nasal drug products (OINDPs), entered a collaboration with Fluidda, a company in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. FDA approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar in 2019, as part of t...